Obsessive-Compulsive Disorder Indication Strategy Report 2026: SERT, mGluR5 and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

PTSD Indication Strategy Report 2026: NMDA, CRHR1, Trials and $1.2B Deal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Generalized Anxiety Disorder Indication Strategy Report 2026: GABA-A, SERT and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Schizophrenia Indication Strategy Report 2026: D2, M1, TAAR1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Bipolar Disorder Indication Strategy Report 2026: GSK-3β, Cav1.2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Treatment-Resistant Depression Indication Strategy Report 2026: NMDA, AMPA and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Major Depressive Disorder Indication Strategy Report 2026: SERT, NMDA, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Cluster Headache Indication Strategy Report 2026: CGRP, PACAP, Trials and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Migraine Indication Strategy Report 2026: CGRP, PACAP, Trials and Deal Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Lennox-Gastaut Syndrome Indication Strategy Report 2026: GABA-A, SV2A and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Dravet Syndrome Indication Strategy Report 2026: Nav1.1, SCN1A, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Epilepsy Indication Strategy Report 2026: GABA-A, SV2A, Nav1.1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.